Trial · NCT03268954
Results by group134
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 134
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-Free Survival (EFS) | Azacitidine 75 mg/m^2 | 15.7 | 95% Confidence Interval 14.42 to 19.68 | months | |
| Event-Free Survival (EFS) | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 17.7 | 95% Confidence Interval 13.63 to 20.24 | months | |
| Overall Survival (OS) | Azacitidine 75 mg/m^2 | 16.8 | 95% Confidence Interval 14.92 to 20.11 | months | |
| Overall Survival (OS) | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 20.3 | 95% Confidence Interval 17.97 to 22.60 | months | |
| Kaplan-Meier Estimates of Six-Month Survival Rate | Azacitidine 75 mg/m^2 | 0.825 | 95% Confidence Interval 0.767 to 0.869 | percentage probability | |
| Kaplan-Meier Estimates of Six-Month Survival Rate | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 0.810 | 95% Confidence Interval 0.752 to 0.856 | percentage probability | |
| Kaplan-Meier Estimates of One-Year Survival Rate | Azacitidine 75 mg/m^2 | 0.693 | 95% Confidence Interval 0.626 to 0.751 | percentage probability | |
| Kaplan-Meier Estimates of One-Year Survival Rate | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 0.646 | 95% Confidence Interval 0.578 to 0.706 | percentage probability | |
| Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | Azacitidine 75 mg/m^2 | 6 | Participants | ||
| Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 5 | Participants | ||
| Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | Azacitidine 75 mg/m^2 | 15 | Participants | ||
| Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 14 | Participants | ||
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Azacitidine 75 mg/m^2 | HR MDS Participants | 35.6 | 95% Confidence Interval 26.51 to NA | months |
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | HR MDS Participants | NA | 95% Confidence Interval 23.29 to NA | months |
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Azacitidine 75 mg/m^2 | HR CMML Participants | NA | 95% Confidence Interval NA to NA | months |
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | HR CMML Participants | NA | 95% Confidence Interval NA to NA | months |
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Azacitidine 75 mg/m^2 | HR MDS/CMML Participants | 35.6 | 95% Confidence Interval 29.04 to NA | months |
| Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | HR MDS/CMML Participants | NA | 95% Confidence Interval 24.28 to NA | months |
| Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi) | Azacitidine 75 mg/m^2 | 71 | Participants | ||
| Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi) | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 63 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03268954/results